@phdthesis{Rettig2010,
  author    = {Michael Rettig},
  title     = {Thermodynamic and NMR Structural Studies on the DNA Binding of Bifunctional Drugs with Alkylating Activity},
  journal    = {Thermodynamische und NMR-strukturelle Untersuchungen zur DNA-Anbindung von bifunktionalen Wirkstoffen mit alkylierender Aktivit{\"a}t},
  url       = {https://nbn-resolving.org/urn:nbn:de:gbv:9-000766-7},
  year      = {2010},
  abstract  = {Pyrrolobenzodiazepines (PBDs) are a group of antitumor antibiotics that exert their biological activity by alkylation of guanine bases within the minor groove of double-stranded DNA through nucleophilic attack of the guanine amino group on the PBD imine functionality. In trying to increase both the binding strength and sequence selectivity for further enhancing their biological activity, PBDs were linked to additional DNA binding moieties. Preliminary DNA melting experiments partly also performed in our lab with a series of closely related PBD-naphthalimide and benzimidazole conjugates revealed extraordinary DNA-binding capability of hybrids PBD-NIM and PBD-BIMZ. These studies also indicated the favorable contribution of the piperazine structure on drug binding to the DNA duplex. Previously, in vitro cytotoxicity studies also showed promising antitumor activity of both compounds with PBD-BIMZ having the largest cytotoxic potential among various examined conjugates. In the present work, the kinetics, thermodynamics and structural details of the drug-DNA interactions have been determined employing a variety of spectroscopic, calorimetric and computational methods. Thus, a high thermal duplex stabilization upon DNA binding could be ascertained for both drugs and attributed to their covalent attachment to the DNA guanine bases. The 1:1 binding stoichiometry as well as the exclusive minor groove binding for the benzimidazole and the mixed minor grove - intercalative type of binding for the naphthalimide hybrid could be verified by several spectroscopic methods including NMR spectroscopy. Furthermore, by using a combination of solution NMR and some of the most recent molecular modeling techniques, the first high-resolution structures of DNA-drug complexes with PBD hybrid drugs could be obtained giving detailed insight into the specific drug-DNA interactions. Thus, details on van der Waals and hydrogen bond contacts within the complex and the tight fit of the benzimidazole hybrid into the DNA minor groove could be revealed. By using recent data analysis techniques like clustering algorithms, the high flexibility of the piperazine moiety within the PBD-BIMZ-DNA complex could be nicely captured and visualized. Additionally, a thermodynamic analysis for the non-covalent drug binding by UV and fluorescence spectroscopy as well as by direct calorimetric methods revealed a 1:1 binding mode driven by enthalpy changes and counteracted by unfavorable entropic contributions to result in moderately strong association constants. Analysis of the solvent-accessible surface area confirmed the importance of hydrophobic effects on drug binding and the combination of these data with ITC measurements allowed for an extensive thermodynamic characterization of the drug binding process. With respect to the influence of the individual drug moieties on DNA binding, the importance of the piperazine ring for drug-DNA interactions and the basis for its capability to enhance drug binding were addressed. Furthermore, it could be shown that the naphthalimide and benzimidazole moieties also impart additional sequence selectivity to the alkylating PBD structural unit and these distinct differences in the sequence selectivity could be linked to the three-dimensional structures of the DNA-drug complexes. Clearly, the combination of detailed structural and thermodynamic data of complex formation allows for a better understanding of the binding mechanism and structure-activity relationship when it comes to drug-DNA interactions. Therefore, the information gathered can assist in the design of more efficient derivatives of this type of alkylating DNA binding drugs in particular and of DNA recognition by ligands composed of several motifs in general.},
  language  = {en}
}